By signing the Copyright Letter the authors retain the rights of self-archiving. Following are the important features of self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites, their institution’s repositories or any non-commercial repository for personal use, internal institutional use or for permitted scholarly posting.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution’s repository or any non-commercial repository such as PMC, arXiv after 12 MONTHS of publication on the journal website. In addition, an acknowledgement must be given to the original source of publication and a link should be inserted to the published article on the journal's/publisher’s website.
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published version of manuscripts in an institutional repository after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts.
The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=[insert DOI].”
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website.
LONG-TERM ARCHIVING OF BENTHAM SCIENCE CONTENT
To ensure permanent access to our publications, Bentham Science has an agreement with Portico to have a long-term preservation of the content published in its journals.
Giulio Francia The University of Texas El Paso, TX (USA)
Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.